Co-transduction of Apaf-1 and caspase-9 highly enhances p53-mediated apoptosis in gliomas.
Mutation of the p53 gene plays a critical role in the development of cancer and response to cancer therapy. To analyze the mechanism of cancer development and to improve cancer therapy, it is important to assess which genes are downstream components of p53 in cancers, and whether the expression levels of these genes affect p53-mediated apoptosis. In this study, we transduced the wild type p53 gene along with the Apaf-1 and caspase-9 genes via adenovirus vectors into U251 and U-373MG glioma cells harbouring a mutated p53, and evaluated the degree of apoptosis. Co-induction of Apaf-1 and caspase-9 genes highly enhanced p53-mediated apoptosis in glioma cells. Induction of wild type p53 enhanced the expression levels of Bax, p21/WAF1, and Fas protein. To determine which gene is activated by wild type p53 induction and, in turn, activates Apaf-1 and caspase-9, we transduced the Bax, p21/WAF1 or Fas gene via adenovirus vector to U251 cells to achieve a similar expression level as that induced by the Adv for p53 in U251 cells. U251 cells transduced with Fas concomitant with the Apaf-1 and caspase-9 genes underwent drastic apoptosis. This suggests that induction of wild type p53 upregulates Fas, which in turn may play a role in the activation of Apaf-1 and caspase-9. These results are important for analyzing the mechanism of tumour development and for predicting the therapeutic effect of p53 replacement gene therapy in a particular patient.
Shinoura
N
N
Department of Molecular Biotherapy Research, Cancer Chemotherapy Center, Cancer Institute, 1-37-1 Kami-Ikebukuro, Toshima-ku, Tokyo 170-8455, Japan. shinoura-k@komagome-hospital.bunkyo.tokyo.jp
Sakurai
S
S
Shibasaki
F
F
Asai
A
A
Kirino
T
T
Hamada
H
H
D000256:Adenoviridae / Q000235:genetics; D017209:Apoptosis / Q000235:genetics*; D053477:Apoptotic Protease-Activating Factor 1; D001932:Brain Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D001973:Bromodeoxyuridine; D053453:Caspase 9; D020169:Caspases / Q000235:genetics* / Q000378:metabolism; D002470:Cell Survival; D005434:Flow Cytometry; D015870:Gene Expression / Q000502:physiology; D005910:Glioma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D015151:Immunoblotting; D009479:Neuropeptides / Q000378:metabolism; D011506:Proteins / Q000235:genetics* / Q000378:metabolism; D018124:Receptors, Tumor Necrosis Factor; D014161:Transduction, Genetic; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000235:genetics* / Q000378:metabolism; D019014:fas Receptor
C506592:APAF1 protein, human; D053477:Apoptotic Protease-Activating Factor 1; C491901:FAS protein, human; D009479:Neuropeptides; D011506:Proteins; D018124:Receptors, Tumor Necrosis Factor; D016159:Tumor Suppressor Protein p53; D019014:fas Receptor; C506433:CASP9 protein, human; D053453:Caspase 9; D020169:Caspases; D001973:Bromodeoxyuridine